- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02824263
Impact métabolique de la CPAP intermittente (MIIC)
Obstructive sleep apnea is a risk factor for diabetes and cardiovascular disease, by unknown mechanisms. The investigators hypothesize that sleep apnea changes glucose and lipid metabolism during sleep, which over time could lead to diabetes and cardiovascular disease. This study examines metabolic changes during sleep in patients with obstructive sleep apnea. Patients accustomed to continuous positive airway pressure (CPAP) therapy are enrolled to undergo sleep studies, either on CPAP therapy or after withdrawing from CPAP for 3 nights. During sleep, blood samples are obtained so that metabolic function can be compared between sleep apnea and CPAP nights.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Participants with a history of moderate severe sleep apnea (AHI>20) will be enrolled if participants meet inclusion/exclusion criteria. Investigators will report to the sleep laboratory on two nights, (1) after continuing their CPAP or (2) after discontinuing CPAP for 3 nights. The order of observation will be randomized. A standard research dinner is provided before each study. IV's are placed so that blood can be sampled at frequent (30 min) intervals throughout the night. In the morning after each study, a glucose tolerance test and endothelial function study (endoPAT) are performed. Serum samples will be analyzed for glucose, insulin, free fatty acids, triglycerides, hormones, and other metabolic biomarkers.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21224
- Johns Hopkins Bayview Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- History of moderate to severe Obstructive sleep apnea (OSA) (AHI or respiratory disturbance index (RDI)> 10).
- They must also own a CPAP machine and report the ability to tolerate sleeping with or without CPAP during the night.
Exclusion Criteria:
- Uncontrolled hypertension with systolic blood pressure >170 or diastolic blood pressure > 110
- Congestive heart failure
- Use of clonidine or nicotinic acid medication
- Diabetes requiring the use of insulin
- Known pregnancy, by urine testing in women of child-bearing age
- History of falling asleep while driving, near miss
- High risk occupation (pilot, commercial driver)
- Hemoglobin < 10 g/dL on point of care screening
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Aucune intervention: CPAP (Usual care)
Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory. |
|
|
Expérimental: CPAP withdrawal;
Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night. |
CPAP is discontinued for 3 nights. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concentration of Plasma Free Fatty Acids (FFA, mmol/L)
Délai: 2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
|
Concentration of Plasma Glucose (mg/dl)
Délai: 2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
|
Concentration of Plasma Insulin (mcU/ml)
Délai: 2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
|
Concentration of Plasma Triglycerides (mg/dl)
Délai: 2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart. Data from each night was averaged to report a single value.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Oral Glucose Tolerance Test (OGTT)
Délai: 2 nights, <1 month apart. 5 OGTT values were averaged to a obtain a single value.
|
We will report the mean of the area under the curve (AUC) during OGTT for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart. 5 OGTT values were averaged to a obtain a single value.
|
|
Reactive Hyperemia Index (RHI)
Délai: 2 nights, <1 month apart, 1 measurement each visit
|
Measured in the morning using Itamar EndoPAT device. This will measure the ratio of blood flow after brachial artery occlusion to blood flow prior to brachial artery occlusion. Normal values range from approximately 1 to 3 with higher values being associated with better vascular function. We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart, 1 measurement each visit
|
|
Augmentation Index (AI)
Délai: 2 nights, <1 month apart, 1 measurement each visit
|
Measured in the morning using Itamar EndoPAT device. Augmentation index is measured once during each visit, and is expressed as a % increase in the pressure waveform during systole. We will report the mean for all participants per group (CPAP vs. CPAP withdrawal). |
2 nights, <1 month apart, 1 measurement each visit
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jonathan C Jun, MD, Johns Hopkins University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- NA_00086830
- R01HL135483 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .